Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

The pharmacological treatment of cognitive impairments associated with schizophrenia is still a major unmet clinical need. Indeed, treatments with available antipsychotics generate highly variable cognitive responses among patients with schizophrenia. This has led to the general assumption that anti...

Descripción completa

Detalles Bibliográficos

Autores principales:	Sebastiano Alfio Torrisi, Samuele Laudani, Gabriella Contarini, Angelina De Luca, Federica Geraci, Francesca Managò, Francesco Papaleo, Salvatore Salomone, Filippo Drago, Gian Marco Leggio
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2020-11-01
Colección:	Pharmaceuticals
Materias:	cognition schizophrenia dopamine receptors second-generation antipsychotics
Acceso en línea:	https://www.mdpi.com/1424-8247/13/11/365
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!